With 0.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.06 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $504.31 whereas the lowest price it dropped to was $488.06. The 52-week range on VRTX shows that it touched its highest point at $510.64 and its lowest point at $341.90 during that stretch. It currently has a 1-year price target of $521.04. Beta for the stock currently stands at 0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VRTX was up-trending over the past week, with a rise of 5.56%, but this was up by 7.37% over a month. Three-month performance surged to 7.26% while six-month performance rose 19.92%. The stock gained 32.84% in the past year, while it has gained 23.49% so far this year. A look at the trailing 12-month EPS for VRTX yields -1.99 with Next year EPS estimates of 18.82. For the next quarter, that number is 4.06. This implies an EPS growth rate of -96.91% for this year and 3897.10% for next year. EPS is expected to grow by 12.49% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 11.42%.
Float and Shares Shorts:
At present, 257.70 million VRTX shares are outstanding with a float of 257.44 million shares on hand for trading. On 2024-10-15, short shares totaled 4.29 million, which was 166.0 higher than short shares on 1726185600. In addition to Dr. Jeffrey Marc Leiden M.D., Ph.D. as the firm’s Executive Chairman, Dr. Reshma Kewalramani FASN, M.D. serves as its CEO, President & Director.
Institutional Ownership:
Through their ownership of 0.95489 of VRTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, VRTX reported revenue of $2771900000.0 and operating income of $1131600000.0. The EBITDA in the recently reported quarter was $1300100000.0 and diluted EPS was $4.01.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VRTX since 16 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VRTX analysts setting a high price target of 602.0 and a low target of 325.0, the average target price over the next 12 months is 515.77. Based on these targets, VRTX could surge 19.81% to reach the target high and fall by -35.32% to reach the target low. Reaching the average price target will result in a growth of 2.65% from current levels.
Analysts have provided yearly estimates in a range of $2.30105 being high and -$0.39549 being low. For VRTX, this leads to a yearly average estimate of $0.4674.
